Xeris Pharmaceuticals Earnings Call Highlights Rapid Growth

Xeris Pharmaceuticals ((XERS)) has held its Q4 earnings call. Read on for the main highlights of the call.

Xeris Pharmaceuticals’ latest earnings call struck an upbeat tone as management celebrated 44% full‑year revenue growth, its first full‑year net profit, and expanding margins. Executives balanced this optimism with frank discussion of higher near‑term spending and legal uncertainty around Recorlev patents, but framed these as investments and risks in service of outsized long‑term growth.

Surging Top Line Backed by Strong Q4 Finish

Full‑year 2025 revenue jumped to $291.8 million, up 44% year over year, underscoring accelerating commercial momentum across the portfolio. Fourth‑quarter revenue of $85.8 million climbed 43%, giving investors reassurance that growth exiting the year remains robust rather than front‑loaded.

Recorlev Emerges as the Main Growth Engine

Recorlev led the charge with Q4 sales of $45.3 million and full‑year revenue of $139.3 million, more than doubling in both periods. The patient base ended 2025 at roughly 700, nearly twice the prior year’s level, cementing Recorlev as the company’s primary growth driver and key value creation asset.

Gvoke and Keveyis Provide Steady, Durable Cash Flows

Gvoke delivered $24.6 million in Q4 and $94.1 million for 2025, growing 14% and providing a more predictable revenue stream. Keveyis contributed $12.8 million in Q4 and $47.6 million for the year, with growth coming mainly from increases in the average number of patients on therapy rather than rapid volume expansion.

First Full‑Year Net Income Marks Profitability Milestone

The company posted net income for the full year 2025 alongside adjusted EBITDA of $59.4 million, signaling a step change in profitability. Fourth‑quarter adjusted EBITDA of $25.1 million improved by $16.8 million year over year, showcasing improving operating leverage even as the company continues to invest.

Gross Margins Remain High and Are Still Improving

Gross margin reached 87% in Q4 and 85% for the full year, up from the prior period on the back of a favorable shift in product mix. Management highlighted these high margins as a key pillar enabling the firm to absorb higher R&D and SG&A while staying profitable on an adjusted basis.

Balance Sheet Strength Supports Self‑Sustaining Model

Management emphasized that 2025 marked the transition to financial self‑sustainability, with operating cash flows now supporting growth ambitions. A stronger balance sheet gives the company flexibility to fund XP‑8121 development, expand commercial infrastructure, and pursue opportunities without relying heavily on external financing.

Ambitious 2026 Targets Signal Confidence in Growth

Guidance calls for 2026 revenue of $375 million to $390 million, implying more than 30% growth at the midpoint versus 2025. The company also expects to remain adjusted‑EBITDA positive and to increase adjusted‑EBITDA dollars, suggesting that growth investments will not derail profitability.

XP‑8121 Positioned as a High‑Value Future Catalyst

XP‑8121, a key pipeline asset, is on track to enter Phase III in the second half of 2026 with projected peak sales between $1 billion and $3 billion. Management sees a target pool among the roughly 20 million hypothyroid patients on oral therapy, including 3 million to 5 million who struggle to maintain normal ranges due to gastrointestinal absorption issues.

Commercial Expansion Aims to Accelerate Recorlev Uptake

To unlock further growth, Xeris nearly doubled its Recorlev commercial team in January 2026 across sales, patient support, medical affairs, and pharmacy services. Management expects these investments to begin materially impacting prescriptions and revenue in the second half of 2026 and in subsequent years.

Strengthening Recorlev Intellectual Property Defenses

The company is working to protect Recorlev’s long‑term value by citing four Orange Book‑listed patents extending to March 2040 and relying on orphan exclusivity through late 2028. Management has initiated a patent infringement lawsuit against two generic filers, underscoring its intent to vigorously defend the franchise.

Patent Litigation and Execution Risks Around Recorlev

While confident in its intellectual property, management acknowledged that the newly filed suit introduces timing and outcome uncertainty that could linger for months or years. This legal overhang, combined with Recorlev’s outsized role in growth, represents a notable execution risk that investors will be monitoring closely.

Concentration Around a Single Growth Engine

With Recorlev delivering more than 100% growth and the majority of incremental revenue, Xeris now faces meaningful product concentration risk. Any competitive, regulatory, or reimbursement shock to this franchise could disproportionately impact overall performance despite diversification from Gvoke and Keveyis.

R&D Ramp to Advance XP‑8121 Phase III

R&D spending totaled $31.2 million in 2025, up 22%, and is set to rise by about $25 million in 2026 as XP‑8121 moves toward Phase III. This represents a substantial near‑term investment that will weigh on expenses but could unlock a multi‑billion‑dollar opportunity if clinical and commercial execution succeed.

Higher SG&A to Fund Broader Commercial Footprint

Selling, general, and administrative expense reached $47.5 million in Q4 and $182.4 million for the year, growing in the low‑teens range. Management plans roughly a $45 million SG&A increase in 2026 to support Recorlev scaling and broader field presence, expecting operating leverage to show more fully after this build‑out phase.

Growth Moderation in Legacy Products Gvoke and Keveyis

Keveyis appears to be flattening as a contributor, while Gvoke’s 14% full‑year growth indicates more modest upside compared with Recorlev. These trends suggest that incremental revenue and valuation upside will hinge increasingly on Recorlev performance and successful pipeline execution rather than legacy product acceleration.

Seasonal Headwinds Likely to Temper Early‑Year Results

Management flagged typical first‑quarter payer and copay resets that have already slowed early 2026 demand. Investors should therefore expect some seasonality and short‑term lumpiness in early‑quarter numbers, even as full‑year growth expectations remain elevated.

Guidance Underscores Growth and Investment Balance in 2026

For 2026, Xeris expects total revenue of $375 million to $390 million, modestly higher gross margins, and adjusted‑EBITDA that exceeds the 2025 level of $59.4 million. The outlook incorporates about $25 million more R&D and $45 million more SG&A to fund XP‑8121 Phase III initiation and a larger commercial footprint, while partnerships and other revenue are expected to remain around 5% to 10% of the total.

Xeris’ earnings call painted the picture of a company shifting from proof‑of‑concept growth story to a profitable, self‑funded specialty pharma platform. Investors will need to weigh the strong revenue momentum, high margins, and pipeline potential of XP‑8121 against legal and concentration risks around Recorlev and a near‑term step‑up in operating expenses.